King's College London

Research portal

UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

Research output: Contribution to journalArticlepeer-review

Standard

UK Medical Cannabis Registry : an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. / Harris, Michael; Erridge, Simon; Ergisi, Mehmet et al.

In: Expert review of clinical pharmacology, 23.12.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Harris, M, Erridge, S, Ergisi, M, Nimalan, D, Kawka, M, Salazar, O, Ali, R, Loupasaki, K, Holvey, C, Coomber, R, Usmani, A, Sajad, M, Rucker, JJ, Platt, M & Sodergren, MH 2021, 'UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions', Expert review of clinical pharmacology. https://doi.org/10.1080/17512433.2022.2017771

APA

Harris, M., Erridge, S., Ergisi, M., Nimalan, D., Kawka, M., Salazar, O., Ali, R., Loupasaki, K., Holvey, C., Coomber, R., Usmani, A., Sajad, M., Rucker, J. J., Platt, M., & Sodergren, M. H. (2021). UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert review of clinical pharmacology. https://doi.org/10.1080/17512433.2022.2017771

Vancouver

Harris M, Erridge S, Ergisi M, Nimalan D, Kawka M, Salazar O et al. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert review of clinical pharmacology. 2021 Dec 23. https://doi.org/10.1080/17512433.2022.2017771

Author

Harris, Michael ; Erridge, Simon ; Ergisi, Mehmet et al. / UK Medical Cannabis Registry : an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. In: Expert review of clinical pharmacology. 2021.

Bibtex Download

@article{4365d13c66224c6595eb3e8b17466a8a,
title = "UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions",
abstract = "OBJECTIVES: To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs).METHODS: A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050.RESULTS: 190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0-442.0mg) and 20.0mg (range:0.0-188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event.CONCLUSION: An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability.",
author = "Michael Harris and Simon Erridge and Mehmet Ergisi and Devaki Nimalan and Michal Kawka and Oliver Salazar and Rayyan Ali and Katerina Loupasaki and Carl Holvey and Ross Coomber and Azfer Usmani and Mohammed Sajad and Rucker, {James J} and Michael Platt and Sodergren, {Mikael H}",
note = "Funding Information: JJ Rucker is a consultant psychiatrist, a director and a shareholder at Sapphire Medical Clinics, an honorary consultant psychiatrist at The South London & Maudsley NHS Foundation Trust, and an NIHR Clinician Scientist Fellow at the Centre for Affective Disorders at King{\textquoteright}s College London. JJ Rucker is funded by a fellowship (CS-2017-17-007) from the National Institute for Health Research (NIHR). JJ Rucker leads the Psychedelic Trials Group at King{\textquoteright}s College London. King{\textquoteright}s College London receives grant funding from COMPASS Pathways PLC to undertake phase 1 and phase 2 trials with psilocybin. COMPASS Pathways PLC has paid for JJ Rucker to attend trial related meetings and conferences to present the results of research using psilocybin. JJ Rucker has undertaken paid consultancy work for Beckley PsyTech and Clerkenwell Health. Payments for consultancy work are received and managed by King{\textquoteright}s College London and JJ Rucker does not benefit personally. JJ Rucker has no shareholdings in pharmaceutical companies. M Platt is a consultant in pain services and a director and shareholder at Sapphire Medical Clinics, and has no shareholdings in pharmaceutical companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
month = dec,
day = "23",
doi = "10.1080/17512433.2022.2017771",
language = "English",
journal = "Expert review of clinical pharmacology",
issn = "1751-2433",
publisher = "Taylor & Francis",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - UK Medical Cannabis Registry

T2 - an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

AU - Harris, Michael

AU - Erridge, Simon

AU - Ergisi, Mehmet

AU - Nimalan, Devaki

AU - Kawka, Michal

AU - Salazar, Oliver

AU - Ali, Rayyan

AU - Loupasaki, Katerina

AU - Holvey, Carl

AU - Coomber, Ross

AU - Usmani, Azfer

AU - Sajad, Mohammed

AU - Rucker, James J

AU - Platt, Michael

AU - Sodergren, Mikael H

N1 - Funding Information: JJ Rucker is a consultant psychiatrist, a director and a shareholder at Sapphire Medical Clinics, an honorary consultant psychiatrist at The South London & Maudsley NHS Foundation Trust, and an NIHR Clinician Scientist Fellow at the Centre for Affective Disorders at King’s College London. JJ Rucker is funded by a fellowship (CS-2017-17-007) from the National Institute for Health Research (NIHR). JJ Rucker leads the Psychedelic Trials Group at King’s College London. King’s College London receives grant funding from COMPASS Pathways PLC to undertake phase 1 and phase 2 trials with psilocybin. COMPASS Pathways PLC has paid for JJ Rucker to attend trial related meetings and conferences to present the results of research using psilocybin. JJ Rucker has undertaken paid consultancy work for Beckley PsyTech and Clerkenwell Health. Payments for consultancy work are received and managed by King’s College London and JJ Rucker does not benefit personally. JJ Rucker has no shareholdings in pharmaceutical companies. M Platt is a consultant in pain services and a director and shareholder at Sapphire Medical Clinics, and has no shareholdings in pharmaceutical companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021/12/23

Y1 - 2021/12/23

N2 - OBJECTIVES: To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs).METHODS: A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050.RESULTS: 190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0-442.0mg) and 20.0mg (range:0.0-188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event.CONCLUSION: An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability.

AB - OBJECTIVES: To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs).METHODS: A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-value<0.050.RESULTS: 190 patients were included. Median initial Δ9-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0-442.0mg) and 20.0mg (range:0.0-188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event.CONCLUSION: An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability.

UR - http://www.scopus.com/inward/record.url?scp=85122517060&partnerID=8YFLogxK

U2 - 10.1080/17512433.2022.2017771

DO - 10.1080/17512433.2022.2017771

M3 - Article

C2 - 34937477

JO - Expert review of clinical pharmacology

JF - Expert review of clinical pharmacology

SN - 1751-2433

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454